Introducing the Alba® Primary Packaging Platform. Part 1: Particle Release Evaluation | PDA Journal of Pharmaceutical Science and Technology

Reference

1.↵
1. Ciociola A. A.,
2. Cohen L. B.,
3. Kulkarni P.,
4. Kefalas C.,
5. Buchman A.,
6. Burke C.
; FDA-Related Matters Committee of the American College of Gastroenterology. How Drugs are Developed and Approved by the FDA: Current Process and Future Directions. Am. J. Gastroenterol. 2014, 109 (5), 620–623.
OpenUrl Google Scholar
2.↵
1. Sittampalam G. S.,
2. Coussens N. P.,
3. Brimacombe K.,
4. Grossman A.,
5. Arkin M.,
6. Auld D.,
7. et al
1. Strovel J.,
2. Sittampalam S.,
3. Coussens N. P.,
4. Hughes M.,
5. Inglese J.,
6. Kurtz A.,
7. et al
. Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies. In Assay Guidance Manual [Internet], Sittampalam G. S., Coussens N. P., Brimacombe K., Grossman A., Arkin M., Auld D., et al., Eds.; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, 2004. Accessed Nov. 13, 2017; available from: http://www.ncbi.nlm.nih.gov/books/NBK92015/.
Google Scholar
3.↵
1. DiMasi J.
New Drug Development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 2001, 69 (5), 286–296.
OpenUrl CrossRef PubMed Web of Science Google Scholar
4.↵
1. Randolph T. W.,
2. Carpenter J. F.
Engineering Challenges of Protein Formulations. AIChE J. 2007, 53 (8), 1902–1907.
OpenUrl Google Scholar
5.↵
1. Lubiniecki A.,
2. Volkin D. B.,
3. Federici M.,
4. Bond M. D.,
5. Nedved M. L.,
6. Hendricks L.,
7. Mehndiratta P.,
8. Bruner M.,
9. Burman S.,
10. Dalmonte P.,
11. Kline J.,
12. Ni A.,
13. Panek M. E.,
14. Pikounis B.,
15. Powers G.,
16. Vafa O.,
17. Siegel R.
Comparability Assessments of Process and Product Changes Made during Development of Two Different Monoclonal Antibodies. Biologicals 2011, 39 (1), 9–22.
OpenUrl PubMed Google Scholar
6.↵
1. Sacha G. A.,
2. Saffell-Clemmer W.,
3. Abram K.,
4. Akers M. J.
Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems. Pharm. Dev. Technol. 2010, 15 (1), 6–34.
OpenUrl PubMed Google Scholar
7.↵
1. Gerhardt A.,
2. Nguyen B. H.,
3. Lewus R.,
4. Carpenter J. F.,
5. Randolph T. W.
Effect of the Siliconization Method on Particle Generation in a Monoclonal Antibody Formulation in Pre-filled Syringes. J. Pharm. Sci. 2015, 104 (5), 1601–1609.
OpenUrl Google Scholar
8.↵
1. Ennis R. D.,
2. Pritchard R.,
3. Nakamura C.,
4. Coulon M.,
5. Yang T.,
6. Visor G. C.,
7. Lee W. A.
Glass Vials for Small Volume Parenterals: Influence of Drug and Manufacturing Processes on Glass Delamination. Pharm. Dev. Technol. 2001, 6 (3), 393–405.
OpenUrl PubMed Google Scholar
9.↵
1. Jiang Y.,
2. Nashed-Samuel Y.,
3. Li C.,
4. Liu W.,
5. Pollastrini J.,
6. Mallard D.,
7. Wen Z. Q.,
8. Fujimori K.,
9. Pallitto M.,
10. Donahue L.,
11. Chu G.,
12. Torraca G.,
13. Vance A.,
14. Mire-Sluis T.,
15. Freund E.,
16. Davis J.,
17. Narhi L.
Tungsten-Induced Protein Aggregation: Solution Behavior. J. Pharm. Sci. 2009, 98 (12), 4695–4710.
OpenUrl CrossRef PubMed Google Scholar
10.↵
1. Felsovalyi F.,
2. Janvier S.,
3. Jouffray S.,
4. Soukiassian H.,
5. Mangiagalli P.
Silicone-Oil-Based Subvisible Particles: Their Detection, Interactions, and Regulation in Prefilled Container Closure Systems for Biopharmaceuticals. J. Pharm. Sci. 2012, 101 (12), 4569–4583.
OpenUrl PubMed Google Scholar
11.↵
1. Bee J. S.,
2. Randolph T. W.,
3. Carpenter J. F.,
4. Bishop S. M.,
5. Dimitrova M. N.
Effects of Surfaces and Leachables on the Stability of Biopharmaceuticals. J. Pharm. Sci. 2011, 100 (10), 4158–4170.
OpenUrl Google Scholar
12.↵
1. Rauk A. P.,
2. Griffiths K. L.,
3. Gossage M. D.,
4. Weiss W. F.
Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development. J. Pharm. Sci. 2016, 105 (11), 3296–3303.
OpenUrl Google Scholar
13.↵
Research and Markets. Global Prefilled Syringes Market, Analysis & Forecast, 2017–2021 (Focus on Type, Design, Material both (Value & Volume) and Patent Landscape). https://www.researchandmarkets.com/research/43j73w/global_prefilled (accessed Nov 13, 2017), 2017; Available from: https://www.researchandmarkets.com/research/43j73w/global_prefilled.
Google Scholar
14.↵
1. Zadbuke N.,
2. Shahi S.,
3. Gulecha B.,
4. Padalkar A.,
5. Thube M.
Recent Trends and Future of Pharmaceutical Packaging Technology. J. Pharm. Bioallied Sci. 2013, 5 (2), 98.
OpenUrl Google Scholar
15.↵
1. Gallo R.
A Breakthrough Coating Technology for High-Demanding Drugs. 2018 PDA Glass Quality Conference, Washington, DC, January 23, 2018.
Google Scholar
16.↵
1. Adler M.
Challenges in the Development of Pre-filled Syringes for Biologics from a Formulation Scientist's Point of View. Am. Pharm. Rev. 2012, 15 (1), 96.
OpenUrl Google Scholar
17.↵
1. Colas A.,
2. Aguadisch L.
Silicones in Pharmaceutical Applications. Chim. Nouv. 1997, 15 (58), 1779.
OpenUrl Google Scholar
18.↵
1. Shi G. H.,
2. Shinkle S. L.,
3. Gopalrathnam G.,
4. Dong X.,
5. Hofer J. D.,
6. Jensen E. C.,
7. Rajagopalan N.
Impact of Formulation Variables on Silicone Oil Distribution and Functionality of Prefilled Syringe System. PDA J. Pharm. Sci. Technol. 2017, 72 (1), 50–61.
OpenUrl Google Scholar
19.↵
1. Thirumangalathu R.,
2. Krishnan S.,
3. Ricci M. S.,
4. Brems D. N.,
5. Randolph T. W.,
6. Carpenter J. F.
Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 2009, 98 (9), 3167–3181.
OpenUrl CrossRef PubMed Web of Science Google Scholar
20.↵
1. Krayukhina E.,
2. Tsumoto K.,
3. Uchiyama S.,
4. Fukui K.
Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins. J. Pharm. Sci. 2015, 104 (2), 527–535.
OpenUrl PubMed Google Scholar
21.↵
1. Teska B. M.,
2. Brake J. M.,
3. Tronto G. S.,
4. Carpenter J. F.
Aggregation and Particle Formation of Therapeutic Proteins in Contact with a Novel Fluoropolymer Surface versus Siliconized Surfaces: Effects of Agitation in Vials and in Prefilled Syringes. J. Pharm. Sci. 2016, 105 (7), 2053–2065.
OpenUrl Google Scholar
22.↵
1. Funke S.,
2. Matilainen J.,
3. Nalenz H.,
4. Bechtold-Peters K.,
5. Mahler H.-C.,
6. Friess W.
Silicone Migration from Baked-on Silicone Layers. Particle Characterization in Placebo and Protein Solutions. J. Pharm. Sci. 2016, 105 (12), 3520–3531.
OpenUrl Google Scholar
23.↵
1. Gerhardt A.,
2. Mcgraw N. R.,
3. Schwartz D. K.,
4. Bee J. S.,
5. Carpenter J. F.,
6. Randolph T. W.
Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.
OpenUrl Google Scholar
24.↵
1. Jones L. S.,
2. Kaufmann A.,
3. Middaugh C. R.
Silicone oil induced aggregation of proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.
OpenUrl CrossRef PubMed Google Scholar
25.↵
1. Depaz R. A.,
2. Chevolleau T.,
3. Jouffray S.,
4. Narwal R.,
5. Dimitrova M. N.
Cross-Linked Silicone Coating: A Novel Prefilled Syringe Technology That Reduces Subvisible Particles and Maintains Compatibility with Biologics. J. Pharm. Sci. 2014, 103 (5), 1384–1393.
OpenUrl PubMed Google Scholar
26.↵
Particulate Contamination: Sub-visible Particles (reference 04/2011: 20919). In European Pharmacopoeia, 9th ed. (official on January 2017).
Google Scholar
27.↵
<788> Particulate matters in injection. In United States Pharmacopeia (USP) 40; United States Pharmacopeial Convention: Rockville, MD, 2017.
Google Scholar
28.↵
<789> Particles in ophthalmic solutions. In United States Pharmacopeia (USP) 40; United States Pharmacopeial Convention: Rockville, MD, 2017.
Google Scholar
29.↵
6.07. Insoluble Particulate Matter Test for Injections. In The Japanese Pharmacopoeia, 15th ed.; pp. 111–113.
Google Scholar
30.↵
1. Bureau C.
Method of Handling a Liquid Drug Formation. U.S. Patent 2016/0251261 A1, 2016.
Google Scholar
31.↵
1. Sharma D. K.,
2. King D.,
3. Oma P.,
4. Merchant C.
Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations. AAPS J. 2010, 12 (3), 455–464.
OpenUrl PubMed Google Scholar
32.↵
ISO 4802-2:2010 Glassware—Hydrolytic resistance of the interior surfaces of glass containers— Part 2: Determination by flame spectrometry and classification, 2010–04; International Organization for Standardization: Geneva, Switzerland. https://www.iso.org/standard/50308.html.
Google Scholar
33.↵
European Pharmacopoeia, 9^th Ed. (official on January 2017) Glass Containers for Pharmaceutical Use (reference 04/2015: 30201).
Google Scholar
34.↵
ISO 2859-1:1999(E) Sampling procedures for inspection by attributes, 1999-11-15, International Organization for Standardization: Geneva, Switzerland. https://www.iso.org/standard/1141.html.
Google Scholar
35.↵
ICH Guidelines. Available at: http://www.ich.org/products/guidelines.html. Accessed December 22, 2017.
Google Scholar
36.↵
SADC guideline for stability testing. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ABOUT_ICH/Organisation/SADC/Guideline_for_Stability_Studies.pdf. Accessed December 22, 2017.
Google Scholar
37.↵
ASTM F1980-07 (2011) Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices, 2011, ASTM International: West Conshohocken, PA. http://www.astm.org/cgi-bin/resolver.cgi?F1980-07 (2011).
Google Scholar
38.↵
1. Carpenter J. F.,
2. Randolph T. W.,
3. Jiskoot W.,
4. Crommelin D. J. A.,
5. Russell Middaugh C.,
6. Winter G.,
7. Fan Y. X.,
8. Kirshner S.,
9. Verthelyi D.,
10. Kozlowski S.,
11. Clouse K. A.,
12. Swann P. G.,
13. Rosenberg A.,
14. Cherney B.
Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. J. Pharm. Sci. 2009, 98 (4), 1201–1205.
OpenUrl CrossRef PubMed Google Scholar
39.↵
1. Narhi L. O.,
2. Schmit J.,
3. Bechtold-Peters K.,
4. Sharma D.
Classification of Protein Aggregates. J. Pharm Sci. 2012, 101 (2), 493–498.
OpenUrl CrossRef PubMed Google Scholar